BR112012007860A2 - "anticorpos siglec 15 no tratamento de doença relativa a perda óssea" - Google Patents

"anticorpos siglec 15 no tratamento de doença relativa a perda óssea"

Info

Publication number
BR112012007860A2
BR112012007860A2 BR112012007860A BR112012007860A BR112012007860A2 BR 112012007860 A2 BR112012007860 A2 BR 112012007860A2 BR 112012007860 A BR112012007860 A BR 112012007860A BR 112012007860 A BR112012007860 A BR 112012007860A BR 112012007860 A2 BR112012007860 A2 BR 112012007860A2
Authority
BR
Brazil
Prior art keywords
antibodies
siglec
bone loss
bone
treatment
Prior art date
Application number
BR112012007860A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernard Tremblay Gille
Filion Mario
Stuible Matthew
Original Assignee
Alethia Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43856338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012007860(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alethia Biotherapeutics Inc filed Critical Alethia Biotherapeutics Inc
Publication of BR112012007860A2 publication Critical patent/BR112012007860A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
BR112012007860A 2009-10-06 2010-10-06 "anticorpos siglec 15 no tratamento de doença relativa a perda óssea" BR112012007860A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24896009P 2009-10-06 2009-10-06
US12/580,943 US8168181B2 (en) 2006-02-13 2009-10-16 Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
PCT/CA2010/001586 WO2011041894A1 (en) 2009-10-06 2010-10-06 Siglec 15 antibodies in treating bone loss-related disease

Publications (1)

Publication Number Publication Date
BR112012007860A2 true BR112012007860A2 (pt) 2019-09-24

Family

ID=43856338

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007860A BR112012007860A2 (pt) 2009-10-06 2010-10-06 "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"

Country Status (13)

Country Link
US (6) US8168181B2 (enExample)
EP (1) EP2486060A4 (enExample)
JP (2) JP5855569B2 (enExample)
KR (1) KR20120086297A (enExample)
CN (2) CN102803293B (enExample)
AU (2) AU2010305281C1 (enExample)
BR (1) BR112012007860A2 (enExample)
CA (2) CA2870980A1 (enExample)
IL (1) IL218985A0 (enExample)
MX (1) MX2012004084A (enExample)
NZ (1) NZ599193A (enExample)
RU (1) RU2596392C2 (enExample)
WO (1) WO2011041894A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) † 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
CN103483169A (zh) * 2007-09-28 2014-01-01 第一三共株式会社 用于制备双环γ-氨基酸衍生物的中间体
SG10201605897RA (en) * 2007-10-11 2016-09-29 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
MX2011007342A (es) 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
BR112013008255A2 (pt) 2010-10-05 2018-09-25 Daiichi Sankyo Co Ltd anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
CA2848074A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
US9003797B2 (en) * 2011-11-02 2015-04-14 E L Du Pont De Nemours And Company Use of compositions comprising 1,1,1,2,3-pentafluoropropane and optionally Z-1,1,1,4,4,4-hexafluoro-2-butene in power cycles
KR20140138215A (ko) 2012-03-30 2014-12-03 다이이찌 산쿄 가부시키가이샤 신규 항 Ｓｉｇｌｅｃ-15 항체
NZ631509A (en) * 2012-03-30 2016-09-30 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
US9382331B2 (en) * 2013-12-27 2016-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
US20170129956A1 (en) * 2014-06-18 2017-05-11 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
FR3024731B1 (fr) * 2014-08-08 2019-06-14 International - Drug - Development - Biotech Anticorps anti-ck8 pour utilisation dans le traitement des cancers
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN107427563B (zh) * 2014-12-31 2021-03-02 财团法人生物技术开发中心 人源化α-烯醇酶特异性抗体及用于癌症治疗的方法
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102810368B1 (ko) * 2015-11-10 2025-05-19 예일 유니버시티 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
CN105367658B (zh) * 2015-12-02 2020-06-16 朱进 人源抗唾液酸结合免疫球蛋白样凝集素-9的抗体IgG及其应用
EP3515478B1 (en) * 2016-09-21 2024-02-28 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
GB201901710D0 (en) * 2019-02-07 2019-03-27 Nordic Bioscience As Collagen type 23 assay
CN110386982A (zh) * 2019-04-09 2019-10-29 广东三九脑科医院 鼠抗人Siglec-15蛋白单克隆抗体制备及其用途
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
EP4126938A4 (en) * 2020-03-27 2024-04-10 Biosion, Inc. ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
CN112625131B (zh) * 2020-08-10 2021-08-17 北京鼎成肽源生物技术有限公司 抗人c-Met人鼠嵌合单克隆抗体及其应用
WO2022123394A1 (en) * 2020-12-08 2022-06-16 Guizhou Sinorda Biotechnology Co. Ltd. Modified t cells for adoptive immunotherapy
CN112625132B (zh) * 2021-01-15 2022-08-02 沈阳荣欣生物制药科技有限公司 纳米抗体及其编码基因、表达载体、宿主细胞和应用
IL305409A (en) * 2021-02-23 2023-10-01 Shanghai Jemincare Pharmaceuticals Co Ltd Preparation of SIGLEC-15 binding protein and its use
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
KR20230158058A (ko) * 2021-03-19 2023-11-17 엘피스 바이오파마슈티컬즈 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN117203241A (zh) * 2021-04-22 2023-12-08 上海医药集团股份有限公司 抗Siglec15抗体及其用途
CN114591434B (zh) * 2021-04-30 2023-02-28 杭州邦顺制药有限公司 抗Siglec15抗体及其制备方法和用途
CN115947855B (zh) * 2022-05-20 2023-10-27 杭州邦顺制药有限公司 抗cd24抗体的制备及其用途
GB202209786D0 (en) * 2022-07-04 2022-08-17 Ucl Business Ltd B7H3 Binders
CN120303296A (zh) * 2022-10-02 2025-07-11 瑞美德生物医药科技有限公司 C-c趋化因子受体8型(ccr8)拮抗剂抗体
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5817303A (en) * 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
ES2263204T5 (es) * 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
NZ527414A (en) 1998-03-04 2005-07-29 Genencor Int Modified forms of pullulanase
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US7060433B1 (en) * 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US7534579B2 (en) * 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1200109A4 (en) 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
ES2360155T3 (es) * 2000-01-26 2011-06-01 Agensys, Inc. 84p2a9: una proteína específica de próstata y testículos altamente expresada en el cáncer de próstata.
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US6635448B2 (en) * 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
CA2421200A1 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
CA2428140A1 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
JP4173733B2 (ja) * 2000-12-12 2008-10-29 アンジオラボ・インコーポレイテッド 抗−血管新生およびマトリックスメタロプロテイナーゼ阻害活性を有するメリッサ葉抽出物を含む組成物
US7459539B2 (en) 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1369479A4 (en) 2001-02-15 2004-12-08 Mochida Pharm Co Ltd "NEW CELL ADHESION MOLECULES SPECIFIC FOR ACTIVATED LEUKOCYTES"
EP2105141B1 (en) 2001-03-28 2012-08-08 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6967021B2 (en) 2001-04-27 2005-11-22 Trustees Of Tufts College Use of Galectin-3 to promote the re-epithelialization of wounds
CA2446185C (en) 2001-05-07 2013-06-18 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
WO2002102432A1 (en) * 2001-06-15 2002-12-27 Johns Hopkins Singapore Pte Ltd Biofunctional fibers
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
CA2652991A1 (en) 2001-07-16 2003-11-13 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US7402664B2 (en) 2002-09-03 2008-07-22 Genencor International, Inc. Nucleic acids and expression vectors comprising carotenoid binding peptides
JP4120778B2 (ja) 2001-09-26 2008-07-16 国立大学法人 奈良先端科学技術大学院大学 骨代謝異常疾患マーカー及びその利用
US20050107588A1 (en) * 2001-11-13 2005-05-19 Duggan Brendan M. Receptors and membrane-associated proteins
JP2003210166A (ja) 2001-11-16 2003-07-29 Sanyo Chem Ind Ltd 変温動物由来細胞の細胞接着基材
US20080194489A1 (en) * 2001-12-21 2008-08-14 Khan Nisar A Treatment of iatrogenic disease
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080318871A1 (en) 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242618A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Stratification
AU2003201733B2 (en) 2002-01-09 2008-11-06 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US8298606B2 (en) * 2002-03-08 2012-10-30 The Regents Of The University Of California Methods and compositions for stabilizing the myocardium
KR20030076448A (ko) 2002-03-21 2003-09-26 주식회사 코메드 항-ｒａｎｋ 단클론 항체 및 이를 함유한 약학 조성물
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US20040102608A1 (en) * 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
AU2003239531A1 (en) * 2002-05-17 2003-12-02 Montana State University Protein cages for the delivery of medical imaging and therapy
CN100532549C (zh) * 2002-06-06 2009-08-26 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
US7357929B2 (en) * 2002-06-28 2008-04-15 D. Collen Research Foundation Vzw Placental growth factor as a target for the treatment of osteoporosis
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US20060135433A1 (en) * 2002-10-08 2006-06-22 Murray Christopher J Phenolic binding peptides
US7572894B2 (en) 2002-11-01 2009-08-11 Trustees Of Tufts College Templated native silk smectic gels
MXPA05005920A (es) 2002-12-03 2006-03-17 American Nat Red Cross Ligandos de proteina prion y metodos de uso.
JP2004189848A (ja) 2002-12-10 2004-07-08 Giken:Kk 炭化処理方法および炭化処理システム
US20060051879A9 (en) 2003-01-16 2006-03-09 Hubert Koster Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
JP3906924B2 (ja) 2003-02-28 2007-04-18 独立行政法人農業生物資源研究所 絹タンパクから細胞生育ペプチドの抽出と利用
WO2004085633A1 (en) * 2003-03-24 2004-10-07 The University Of Hong Kong A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
US7547512B2 (en) * 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP4698596B2 (ja) 2003-04-10 2011-06-08 タフツ ユニバーシティー 濃縮された水性シルクフィブロイン溶液およびそれらの使用
EP1627062A1 (en) * 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
JP3915983B2 (ja) 2003-05-27 2007-05-16 ゼライス株式会社 プロテアーゼ、このプロテアーゼをコードするｄｎａ、プロテアーゼの製造方法
US7671011B2 (en) * 2003-06-19 2010-03-02 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
FR2860237B1 (fr) 2003-09-30 2006-03-10 Centre Nat Rech Scient Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US20090226374A1 (en) 2003-10-27 2009-09-10 Health Aide, Inc. Anaphylatoxins for detecting clinical conditions
US20050153333A1 (en) * 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
US20090227505A1 (en) 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2005066337A2 (en) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
US8338138B2 (en) * 2004-01-28 2012-12-25 The John Hopkins University Methods for making and using molecular switches involving circular permutation
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
EP1716181B1 (en) 2004-02-19 2009-12-16 Genentech, Inc. Cdr-repaired antibodies
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
WO2005098043A2 (en) * 2004-03-30 2005-10-20 The President And Fellows Of Harvard College Ligand-dependent protein splicing
AU2005233550B2 (en) * 2004-04-08 2010-11-18 Sangamo Therapeutics, Inc. Treatment of neuropathic pain with zinc finger proteins
US7189697B2 (en) 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
WO2005109158A2 (en) * 2004-05-05 2005-11-17 Massachusetts Institute Of Technology Methods and systems for generating peptides
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
AU2005267734A1 (en) * 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
JP2006068378A (ja) 2004-09-03 2006-03-16 Terumo Corp 血管内留置物
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
AU2005293568B2 (en) * 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
EP1812030A4 (en) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF
EP3061461A1 (en) * 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2006062776A2 (en) 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
US7947436B2 (en) 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
WO2006078746A2 (en) * 2005-01-19 2006-07-27 Mathew Mark Zuckerman Method, compositions and classification for tumor diagnostics and treatment
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
EP1853620B1 (en) * 2005-02-09 2012-01-11 Helix Biomedix, Inc. Antimicrobial hexapeptides
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
EP1874800A4 (en) * 2005-04-26 2009-11-18 Karyon Ctt Ltd DIAGNOSTIC AND THERAPEUTIC AGENTS
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
US8227573B2 (en) 2005-05-20 2012-07-24 University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants
US7528232B2 (en) * 2005-05-20 2009-05-05 The University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in crop plants
AU2006266609C1 (en) * 2005-07-05 2011-10-27 Biotempt B.V. Treatment of tumors
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
WO2007019062A2 (en) 2005-08-11 2007-02-15 The Scripps Research Institute Zinc finger binding domains for cnn
US8445641B2 (en) 2005-08-22 2013-05-21 The United States Of America As Represented By The Secretary Of The Air Force Nanocomposites of repeat sequence proteins and phyllosilicate clays and their preparation
WO2007027954A2 (en) 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US20090275503A1 (en) 2005-09-22 2009-11-05 Yeda Research And Developent Co., Ltd. At The Weizman Institute Of Science Diastereomeric peptides for modulating t cell immunity
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US8137670B2 (en) * 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
JP5047978B2 (ja) 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
US7901942B2 (en) * 2005-11-08 2011-03-08 Tohoku University Method of quantifying membrane protein by mass spectrometry using peptide selection criteria
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
JP2009520463A (ja) 2005-11-28 2009-05-28 ザ スクリプス リサーチ インスティテュート Ｔｎｎのための亜鉛フィンガー結合ドメイン
GB0524313D0 (en) 2005-11-29 2006-01-04 Imp College Innovations Ltd Particles
KR100838715B1 (ko) 2005-12-16 2008-06-16 국립암센터 트란스글루타미나제를 억제하는 펩타이드
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) * 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
EP1986611B1 (en) 2006-02-23 2013-05-01 Danisco US Inc. Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation
WO2007102346A1 (ja) * 2006-02-28 2007-09-13 Japan Science And Technology Agency グルカン量を低減させることなくリグニン量およびセルロース量を低減させた植物体およびその生産方法、並びにこれらの利用
US7501557B1 (en) * 2006-02-28 2009-03-10 University Of Kentucky Research Foundation Method utilizing the tobacco phylloplanin promoter for expression of nucleic acids as gene products directed to aerial surfaces of plants
CA2645277A1 (en) 2006-03-09 2007-09-13 Wadih Arap Compositions and methods based on peptide binding profiling
WO2007108205A1 (ja) * 2006-03-17 2007-09-27 Sanyo Chemical Industries, Ltd. 細胞培養用担体
WO2007111952A2 (en) 2006-03-22 2007-10-04 The Scripps Research Institute Method of preparing glycopeptides
JP2009532027A (ja) 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CA2652247C (en) 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
FR2900826B1 (fr) 2006-05-12 2008-08-15 Soc Extraction Principes Actif Utilisation de peptides en tant que principes actifs amincissants.
WO2007146319A2 (en) 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
KR20090031938A (ko) 2006-07-05 2009-03-30 더 스크립스 리서치 인스티튜트 방향성 진화로 촉매 작용을 최적화시킨 키메라 징크 핑거 리컴비나제
MX2008016352A (es) 2006-07-08 2009-04-17 Univ Kentucky Res Found Analisis diagnostico para cancer de pulmon.
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP2008094822A (ja) 2006-09-15 2008-04-24 Univ Of Tokyo セルロース結合性ペプチドおよびその製造方法
WO2008055225A2 (en) * 2006-10-31 2008-05-08 Musc Foundation For Research Development Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions
CA2668640A1 (en) 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
AU2008206077A1 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US9175422B2 (en) * 2007-01-22 2015-11-03 The United States Of America As Represented By The Secretary Of The Army Polymer-micelle complex as an aid to electrospinning
AU2008211854C1 (en) 2007-01-29 2014-01-23 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP2111413A2 (en) 2007-02-16 2009-10-28 Genetech, Inc. Htra1-pdz and htra3-pdz modulators
DK2146733T3 (da) 2007-03-14 2021-01-11 Arch Biosurgery Inc Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
WO2008112904A2 (en) 2007-03-15 2008-09-18 Invitrogen Corporation Adhering surfaces
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
JP2008263955A (ja) 2007-03-29 2008-11-06 Sanyo Chem Ind Ltd 無血清培地
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
WO2008137122A2 (en) * 2007-05-04 2008-11-13 Shiloh Laoratories, Inc. Inducing premature senescence to stabilize stem cell feeder layer cells
US8097581B2 (en) * 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
WO2008151146A2 (en) * 2007-06-01 2008-12-11 Digitab, Inc. Peptide arrays and methods of use
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
JP5328780B2 (ja) * 2007-06-13 2013-10-30 エフ エム シー コーポレーション アルギネート被覆多糖ゲル含有発泡体複合物、その製法および用途
US20090017460A1 (en) * 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008273096B2 (en) 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
CL2008002085A1 (es) * 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
JP5099138B2 (ja) 2007-08-06 2012-12-12 国立大学法人 筑波大学 花の形態が改変された植物体の生産方法
WO2009023125A1 (en) 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
CN101918007B (zh) 2007-08-28 2014-06-04 Fmc有限公司 延迟的自胶凝藻酸盐体系及其应用
KR100887266B1 (ko) 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
EP2185707B1 (en) 2007-09-04 2013-07-03 Procell Therapeutics Inc. Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
JP5000439B2 (ja) 2007-09-19 2012-08-15 三洋化成工業株式会社 細胞培養用担体
MX2010003110A (es) 2007-09-20 2010-05-19 David Gladstone Inst Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
SG10201605897RA (en) 2007-10-11 2016-09-29 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
GB0720156D0 (en) 2007-10-15 2007-11-28 Univ Nottingham Trent Breast cancer associated antigen
EP2205623B1 (en) * 2007-10-29 2016-03-16 Helix Biomedix Inc. Protective skin care tetrapeptides
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
DK2208073T3 (da) 2007-11-05 2020-03-30 Nordic Bioscience As Biokemiske markører til cvd-risikovurdering
WO2009061130A2 (en) 2007-11-06 2009-05-14 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
US20110262508A1 (en) 2007-11-07 2011-10-27 Paul Michael Watt Antimicrobial compositions, formulations and uses thereof
US20100240057A1 (en) 2007-11-08 2010-09-23 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
AU2008321016B2 (en) 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
FR2925500B1 (fr) 2007-12-21 2011-05-06 Vincience Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2925501B1 (fr) 2007-12-21 2012-12-14 Vincience Peptide activateur de la synthese des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
CA2713089C (en) 2008-01-23 2017-11-21 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
EP2250278B1 (en) 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
WO2009117524A2 (en) 2008-03-18 2009-09-24 The Regents Of The University Of California Sparse matrix system and method for identification of specific ligands or targets
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20090281038A1 (en) 2008-05-09 2009-11-12 University Of Kentucky Research Foundation Phylloplanins Inhibition of Microbial Growth on Organic Materials
KR20110016867A (ko) 2008-05-16 2011-02-18 주식회사 프로셀제약 세포투과성 ｐ２７ 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
EA201100146A1 (ru) 2008-07-04 2011-12-30 Басф Плант Сайенс Гмбх Растения, имеющие улучшенные характеристики урожайности, и способ их получения
KR101783272B1 (ko) 2008-09-17 2017-09-29 젠코어 인코포레이티드 ＩｇＥ-매개된 장애를 치료하기 위한 신규 조성물 및 방법
JP5299956B2 (ja) 2008-09-29 2013-09-25 国立大学法人東北大学 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CA2753702C (en) 2009-03-05 2017-01-03 Medarex, Inc. Fully human antibodies specific to cadm1
MX2011007342A (es) * 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
BR112013008255A2 (pt) * 2010-10-05 2018-09-25 Daiichi Sankyo Co Ltd anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
NZ631509A (en) 2012-03-30 2016-09-30 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies

Also Published As

Publication number Publication date
EP2486060A1 (en) 2012-08-15
IL218985A0 (en) 2012-06-28
JP2016040324A (ja) 2016-03-24
US20140205603A1 (en) 2014-07-24
JP5855569B2 (ja) 2016-02-09
AU2010305281A1 (en) 2012-05-03
US8741289B2 (en) 2014-06-03
WO2011041894A1 (en) 2011-04-14
CN102803293B (zh) 2016-05-18
US8900579B2 (en) 2014-12-02
US9617337B2 (en) 2017-04-11
AU2010305281B2 (en) 2014-06-12
AU2014224071A1 (en) 2014-10-02
KR20120086297A (ko) 2012-08-02
CN106046160A (zh) 2016-10-26
JP2013506428A (ja) 2013-02-28
US20150044722A1 (en) 2015-02-12
US20100104575A1 (en) 2010-04-29
CN102803293A (zh) 2012-11-28
CA2870980A1 (en) 2011-04-14
CA2775793C (en) 2015-02-03
EP2486060A4 (en) 2013-06-12
US20130039915A1 (en) 2013-02-14
US8168181B2 (en) 2012-05-01
RU2012118643A (ru) 2013-11-20
RU2596392C2 (ru) 2016-09-10
MX2012004084A (es) 2012-07-10
AU2010305281C1 (en) 2014-12-04
USRE47672E1 (en) 2019-10-29
US9388242B2 (en) 2016-07-12
US20160289325A1 (en) 2016-10-06
NZ599193A (en) 2014-10-31
CA2775793A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
UA116614C2 (uk) Антитіло до фактора d і його застосування
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
EA201590247A1 (ru) Антитела к siglec-15
CU20100059A7 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
MX369148B (es) Agentes de unión kir3dl2.
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EA200970874A1 (ru) Антитела против склеростина
SG170080A1 (en) Human monoclonal antibodies to o8e
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
WO2008027739A3 (en) Antibodies to ntb-a

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.